Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mogamulizumab and Nivolumab in Solid Cancers
NCT02946671Phase 1Completed
- Sponsor
- The University of Osaka
- Start
- Mar 2016
- Primary completion
- Mar 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of mogamulizumab in gastric adenocarcinoma, Esophageal Squamous Cell Carcinoma (ESCC), non-small cell lung carcinoma (NSCLC) and 2 more (3 cohorts), sponsored by The University of Osaka. Primary endpoints: Number of patients with adverse events including intraoperative and postoperative complications at 30 days and Rate of Foxp3-positive patients in tumor by immunohistochemical analysis at 7 weeks. Started Mar 2016; status: completed.
02
Drugs
mogamulizumab
03
Conditions
gastric adenocarcinomaEsophageal Squamous Cell Carcinoma (ESCC)non-small cell lung carcinoma (NSCLC)renal cell carcinoma (RCC)oral squamous cell carcinoma (OSCC)
Beyond the preview
Go deeper on NCT02946671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02946671.